Clinical Trials Logo

Chemotherapy clinical trials

View clinical trials related to Chemotherapy.

Filter by:

NCT ID: NCT05218226 Recruiting - Clinical trials for Chemotherapy-induced Thrombocytopenia

Avatrombopag for Chemotherapy-induced Thrombocytopenia

Start date: February 10, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of Avatrombopag to treat chemotherapy-induced thrombocytopenia in solid tumors

NCT ID: NCT05216237 Recruiting - Gastric Cancer Clinical Trials

A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer

Start date: February 15, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of Sintilimab combined with apatinib and chemotherapy as First-line or second-line Therapy in Treatment of HER-2 negative MSS Advanced or Metastatic GC or GEJ Cancer. At the same time, the correlation between tissue programmed death ligand-1(PD-L1) expression and blood circulating tumor cell(CTC) counts and the efficacy of immune combination therapy was also explored.

NCT ID: NCT05199818 Recruiting - Clinical trials for Chemotherapy-induced Nausea and Vomiting

Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC

Start date: March 1, 2022
Phase: Phase 3
Study type: Interventional

The phase 3 study is to compare the efficacy and safety of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film delivery compared to IV injection for the prevention of chemotherapy-induced nausea and vomiting. Subjects receive a single dose of palonosetron prior to moderately emetogenic chemotherapy.

NCT ID: NCT05199389 Active, not recruiting - Clinical trials for Chemotherapy-induced Peripheral Neuropathy

Photobiomodulation Therapy in the Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy

NeuroLight
Start date: January 31, 2022
Phase: N/A
Study type: Interventional

This study aims to investigate the effectiveness of photobiomodulation therapy (PBM) in the management of chemotherapy-induced peripheral neuropathy (CIPN). Therefore, the hypothesis is that PBM can reduce the severity of CIPN in cancer patients, increasing the patient's quality of life.

NCT ID: NCT05143554 Recruiting - Clinical trials for Chemotherapy-induced Nausea and Vomiting

Auricular Neurostimulation for Chemotherapy Induced Nausea and Vomiting

Start date: April 29, 2021
Phase: N/A
Study type: Interventional

This study evaluates the efficacy of auricular percutaneous electrical nerve field stimulator in children, adolescents and young adults with chemotherapy induced nausea and vomiting.

NCT ID: NCT05135260 Active, not recruiting - Cancer Clinical Trials

Virtual Reality on Pain, Stress, and Affect in the Infusion Clinic

Start date: November 1, 2021
Phase: N/A
Study type: Interventional

This study will investigate the ability of virtual reality to function as a novel distraction intervention and improve the experience of patients who are receiving chemotherapy in the infusion clinic.

NCT ID: NCT05125055 Recruiting - Chemotherapy Clinical Trials

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Start date: October 1, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

To compare the pathological efficacy of neoadjuvant Toripalimab and Albumin paclitaxel /Cisplatin (TTP) with Docetaxel/ Cisplatin/ 5-flurouracil (TPF) for patients with locally advanced resectable oral squamous cell carcinoma (OSCC), and to determine the safety of neoadjuvant TTP. In order to explore a better protocol of neoadjuvant therapy to improve the efficacy in patients with locally advanced OSCC.

NCT ID: NCT05121558 Recruiting - Clinical trials for Chemotherapy-Induced Peripheral Neuropathy

The Effect of Yoga on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)

Start date: October 29, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to test whether yoga can reduce nerve pain caused by cancer treatment (chemotherapy-induced peripheral neuropathy, or CIPN). Participants will take one of three approaches: - Yoga classes - Educational sessions on the causes and impacts of CIPN, how yoga may help with CIPN, and how different therapies may help with CIPN - Usual care with standard-of-care medications for CIPN The researchers will compare how these different approaches affect participants' balance, their risk of falls, and their quality of life. This study will also measure how much yoga can help the reduced sense of touch caused by CIPN. The functional assessments TUG and CTS can be safely completed either virtually and in-person and will be mandatory for all patients. The functional assessment FRT and QST assessments that can only be completed in-person are optional at these time points.

NCT ID: NCT05095051 Recruiting - Clinical trials for Chemotherapy-induced Peripheral Neuropathy

A Novel Limb Cryocompression System for Prevention of Chemotherapy Induced Peripheral Neuropathy

Start date: November 3, 2021
Phase: N/A
Study type: Interventional

The study aims to investigate the safety and tolerability of limb cryocompression in preventing of Chemotherapy-induced Peripheral Neuropathy via a newly developed limb cryocompression device in healthy subjects and cancer patients. The limb cryocompression device will be tested for its safety in delivering limb cryocompression and efficacy in improving the preservation of peripheral nerves during chemotherapy.

NCT ID: NCT05052398 Recruiting - Clinical trials for Chemotherapy-induced Peripheral Neuropathy

Proof of Principle Study Evaluating Gonyautoxins NEURO SERUM, on Chemotherapy-induced Peripheral Neuropathy

Start date: January 14, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Proof-of-concept study to assess the effects of gonyautoxins (PSP NEURO SERUM) on safety and tactile sensitivity on patients with chemotherapy-induced peripheral neuropathy (CIPN). This is a multicenter, prospective proof-of-concept study in patients with solid tumors affected by CIPN. The study will be divided into two parts: Part 1 will assess the activity and tolerability of PSP NEURO SERUM and part 2 consists of a randomized cohort that will compare the activity of PSP NEURO SERUM vs placebo. Part 2 will depend on the results of part 1. If there are less than 8 responses in part 1, the study will be interrupted, and it will not be recommended to proceed with part 2.